American Society of Hematology

SHERPA: Blue

People

  1. Lesokhin
    Lesokhin
  2. Hassoun
    Hassoun
  3. Giralt
    Giralt
  4. Landau
    Landau
  5. Korde
    Korde
  6. Mailankody
    Mailankody
  7. Hultcrantz
    Hultcrantz
  8. Shah
    Shah
  9. Shah
    Shah
  10. Maclachlan
    Maclachlan

Groups

  1. Center for Hematologic Malignancies (152)
  2. Department of Medicine (152)
  3. Hematologic Malignancies Research (152)
  4. Hematologic Malignancies, Division of (152)
  5. Myeloma (152)
  6. Survivorship Research (103)
  7. Bone Marrow Transplant (96)
  8. Hematology-Oncology Fellows (76)
  9. Epidemiology and Biostatistics (75)
  10. Sloan Kettering Institute Postdocs (73)
Search Within
  1. "Alexander Lesokhin"
Formats
  1. Meeting Abstract (129)
  2. Journal Article (21)
  3. Editorial (1)
  4. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (152)
  2. Department of Medicine (152)
  3. Hematologic Malignancies Research (152)
  4. Hematologic Malignancies, Division of (152)
  5. Myeloma (152)
  6. Survivorship Research (103)

More Groups

People
  1. Alexander Lesokhin (152)
  2. Hani Hassoun (91)
  3. Heather Landau (87)
  4. Sergio Giralt (87)
  5. David Chung (79)
  6. Neha Korde (77)

More People

Years
  1. 2025 (3)
  2. 2024 (26)
  3. 2023 (23)
  4. 2022 (18)
  5. 2021 (13)
  6. 2020 (9)

More Years

Publications
  1. Blood (140)
  2. Blood Advances (12)

Results (152)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Recycling is “bad to the bone” in patients with myeloma
    Editorial

    Miller, K. C.; Lesokhin, A. M.
    Blood (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mutationally enriched regions of the non-coding genome harbor functionally impactful mutations that dysregulate key genes involved in multiple myeloma pathogenesis
    Meeting Abstract

    Blaney, P.; Maclachlan, K. H.; Papadimitriou, M.; Mikulasova, A.; Gagler, D. C.; Braunstein, M. J.; Lahoud, O. B.; Kaminetzky, D.; Wang, Y.; Liu, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase i study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies
    Meeting Abstract

    Richter, J.; Thomas, S. K.; Krishnan, A. Y.; Laubach, J. P.; Cohen, A. D.; Trudel, S.; Costa, L. J.; Bahlis, N. J.; Forsberg, P. A.; Kaedbey, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African ancestry compared with those having European ancestry
    Meeting Abstract

    Maclachlan, K. H.; Papadimitriou, M.; Blaney, P.; Shekarkhand, T.; Chu, T. R.; Poos, A. M.; Brown, E.; Hoering, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2024)

    Fulltext@MSK | Save